Nutri-Genetix Ltd.

London

SUMMARY
Winner of SIX awards in 2021, NGX BodyFuel is The World’s First Genetically Personalised Meal-Shake (patent pending). After successfully launching and selling over 120,000 meals in the UK, NGX is raising capital to open the US market & accelerate the launch of new personalised nutrition products.

IDEA
Everyone is genetically unique, with unique nutrition requirements. Current food supplements are often based on generic food guidelines that are unsuitable for achieving optimal levels of fitness & health. It used to be complex & expensive to determine an individual's unique nutrition targets. And it used to be a hassle to prepare fresh food every day to hit them – especially for busy people.

NGX BodyFuel is The World's First Genetically Personalised Meal-Shake, our patent-pending solution to this problem, based on a simple, at-home DNA Nutrition Test.

We have collected ~1m+ customer data points, sold 120,000+ meals of BodyFuel, developed proprietary gene-nutrition matching technology & for the last 6 months have achieved an average return on ad spend of £3.78 for every £1 spent.

We have secured partnerships with the likes of AMEX, Barclays, F45, Axa & Everyone Active. We have featured in the likes of Vogue, Men's Fitness, Women's Health & Dragon's Den – winning offers from Peter Jones & Touker Suleyman.

Our vision is to perfect individual nutrition, whoever you are, whatever your goal. We use our deep understanding of customer genetics & lifestyle choices to inform our R&D roadmap that aims to improve both customer health, & customer value to NGX.

We are raising with the aim of accelerating customer acquisition, launching new products & establishing a US market presence.

TEAM

We started NGX to make personalised nutrition simple, convenient and affordable, so that everyone has the opportunity to become the best version of themselves. Our ambition is to become the most sought after personalised nutrition brand in the industry.

Jeremy Poland, CEO
9 years experience in management consulting, setting up brands and companies for a number of fortune 250 companies including J&J, Pfizer and Abbott.

Hugo Jones, COO
Serial entrepreneur experienced in leading startups such as Cult Events to million-pound revenue-generating companies.

Olga Hamilton (Part-time), VP of Nutrigenetic Science (FdSc, DipION, mBANT, CNHC Registered, PGDip)
10+ yrs experience as a registered nutritional therapist & thought leader in the emerging field of nutrigenetics – the science behind NGX.

Alex Blyth, Chairman
Extensive experience working in a cross-section of healthcare, pharma & business. Has brought over 50 novel products and brands to market. Including work for Novartis, GSK and J&J. Alex has built three companies and sold two.

Advisers
Scientific: Prof. Roche (UCD), Prof. Muller (UEA), Prof. Karani (UoR)

News

No news articles found.

Discussions

Leave a Reply

Companies House

Company Results (links open in a new window)
Date (document was filed at Companies House) Type Description (of the document filed at Companies House) View / Download (PDF file, link opens in new window)
15 Sep 2022 AA01 Previous accounting period shortened from 28 February 2023 to 31 August 2022
25 Aug 2022 SH01 Statement of capital following an allotment of shares on 18 July 2022
  • GBP 189.963
19 Aug 2022 RESOLUTIONS Resolutions
  • RES11 ‐ Resolution of removal of pre-emption rights
  • RES10 ‐ Resolution of allotment of securities
16 Aug 2022 SH01 Statement of capital following an allotment of shares on 31 March 2022
  • GBP 181.352
15 Aug 2022 RESOLUTIONS Resolutions
  • RES11 ‐ Resolution of removal of pre-emption rights
  • RES10 ‐ Resolution of allotment of securities
16 May 2022 AA Total exemption full accounts made up to 28 February 2022
01 Feb 2022 CS01 Confirmation statement made on 31 January 2022 with updates
14 Sep 2021 AA Total exemption full accounts made up to 28 February 2021
25 Aug 2021 PSC01 Notification of Hugh Jones as a person with significant control on 18 August 2021
13 Apr 2021 CS01 Confirmation statement made on 19 February 2021 with updates
13 Apr 2021 RESOLUTIONS Resolutions
  • RES11 ‐ Resolution of removal of pre-emption rights
  • RES10 ‐ Resolution of allotment of securities
13 Apr 2021 RESOLUTIONS Resolutions
  • RES11 ‐ Resolution of removal of pre-emption rights
  • RES10 ‐ Resolution of allotment of securities
24 Feb 2021 PSC04 Change of details for Mr Alexander William Blyth as a person with significant control on 26 January 2021
24 Feb 2021 PSC04 Change of details for Mr Jeremy Duncan Poland as a person with significant control on 26 January 2021
24 Feb 2021 SH01 Statement of capital following an allotment of shares on 26 January 2021
  • GBP 161.729
24 Jan 2021 SH01 Statement of capital following an allotment of shares on 22 December 2020
  • GBP 149.552
24 Jan 2021 SH01 Statement of capital following an allotment of shares on 17 December 2020
  • GBP 129.598
01 Dec 2020 MA Memorandum and Articles of Association
01 Dec 2020 RESOLUTIONS Resolutions
  • RES01 ‐ Resolution of adoption of Articles of Association
22 Jul 2020 AA Total exemption full accounts made up to 29 February 2020
05 Mar 2020 CS01 Confirmation statement made on 19 February 2020 with updates
05 Mar 2020 SH01 Statement of capital following an allotment of shares on 20 December 2019
  • GBP 128.6
02 Jan 2020 PSC04 Change of details for Mr Alexander William Blyth as a person with significant control on 15 September 2019
17 Dec 2019 SH02 Sub-division of shares on 9 December 2019
16 Dec 2019 RESOLUTIONS Resolutions
  • RES13 ‐ Sub-division of ordinary shares 09/12/2019

Risk Warnings